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Abstract
Aims To replicate the association of genetic variants with estimated glomerular filtration rate (GFR) and albuminuria,
which has been found in recent genome-wide studies in patients with Type 2 diabetes.
Methods We evaluated 16 candidate single nucleotide polymorphisms for estimated GFR in 3028 patients with Type 2
diabetes sampled from clinics across Tayside, Scotland, UK, who were included in the Genetics of Diabetes Audit and
Research Tayside (GoDARTs) study. These single nucleotide polymorphisms were tested for their association with
estimated GFR at entry to the study, with albuminuria, and with time to stage 3B chronic kidney disease (estimated
GFR<45 ml/min/1.73 m2). We also stratified the effects on estimated GFR in patients with (n = 2096) and without
albuminuria (n = 613).
Results rs1260326 in GCKR (b=1.30, P = 3.23E-03), rs17319721 in SHROOM3 (b = 1.28, P-value = 3.18E-03)
and rs12917707 in UMOD (b = 2.0, P-value = 8.84E-04) were significantly associated with baseline estimated GFR.
Analysis of effects on estimated GFR, stratified by albuminuria status, showed that in those without albuminuria
(normoalbuminura; n = 613), UMOD had a significantly stronger effect on estimated GFR (bnormo = 4.03  1.23 vs
balbuminuria = 1.72  0.76, P = 0.002) compared with those with albuminuria, while GCKR (bnormo = 0.45  0.89 vs
balbuminuria = 1.12  0.55, P = 0.08) and SHROOM3 (bnormo = 0.07  0.89 vs balbuminuria = 1.43  0.53,
P = 0.003) had a stronger effect on estimated GFR in those with albuminuria. UMOD was also associated with a
lower rate of transition to stage 3B chronic kidney disease (hazard ratio = 0.83[0.70, 0.99], P = 0.03).
Conclusion The genetic variants that regulate estimated GFR in the general population tend to have similar effects in
patients with Type 2 diabetes and in this latter population, it is important to adjust for albuminuria status while
investigating the genetic determinants of renal function.
Diabet. Med. 30, 1230–1235 (2013)
Introduction
Recent genome-wide association studies have identified
several genetic variants associated with estimated (e)GFR
and chronic kidney disease (CKD). Previous investigations of
these eGFR polymorphisms were typically carried out in
populations where < 10% of patients were diagnosed with
Type 2 diabetes [1]. It remains to be established if these
variants are associated with eGFR in patients with Type 2
diabetes for whom there are different reasons for loss of renal
function, in particular diabetic nephropathy, when compared
with patients without diabetes. Most of these studies are cross-
sectional [2–5], and so clinically relevant dynamic phenotypes
cannot be studied. Longitudinal datasets capturing renal
function can be used to investigate if the genetic variants
identified are associated with a rapid decline in renal function
(end-stage renal disease or stage 3 CKD) in patients with Type
2 diabetes. About 20% of patients with Type 2 diabetes with
CKD defined according to the ADA guidelines may have
normoalbuminuria (albumin/creatinine ratio [ACR] <2.5 mg/
mmol in males and ACR<3.5 mg/mmol in females) [6]. The
genetic and pathological mechanisms that determine the
relationship between reduced eGFR and albuminuria status
in patients with Type 2 diabetes remain unknown [7].
Although the genetic variants associated with eGFR do not
seem to be associated with albuminuria [8], it remains to be
seen if these genetic variants have the same effect on eGFR in
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those with and without albuminuria. In the present study,
using a longitudinal cohort of patients with Type 2 diabetes,
we investigated the association of 16 recently identified eGFR-
associated loci (LASS2, GCKR, NAT8, TFDP2, SHROOM3,
DAB2, SLC34A1, VEGFA, PRKAG2, ADAM28, PIP5K1B,
ATXN2, DACH1, UBE2Q2, UMOD, SLC7A9) with base-
line eGFR albuminuria, and time to stage 3B CKD
(eGFR<45 ml/min/1.73 m2), in patients with Type 2 diabetes.
Methods
The study population comprised 3028 patients with Type 2
diabetes identified from an on-going study, the Genetics of
Diabetes Audit and Research Tayside (GoDARTs) study, and
recruited in Tayside, Scotland, UK, between 1 October 1997
and 1 March 2010. The baseline clinical characteristics of the
GoDARTs subset included in the present analyses were very
similar to the baseline clinical characteristics of the remain-
ing GoDARTS cohort, except that those not included were
slightly older and had a lower eGFR (Table 1); therefore, the
subset of patients used for the present analysis was very
representative of the entire GoDARTs cohort. Calculations
for eGFR were made using the Modification of Diet in Renal
Disease formula [9] which requires age, sex, race and
creatinine data. We assessed the association of the 16 single
nucleotide polymorphisms (SNPs) with eGFR at baseline by
linear regression analysis using the gPLINK program [10],
adjusting for age, sex, BMI, population structure, HbA1c,
duration of diabetes and systolic blood pressure. To inves-
tigate whether the association of these loci with eGFR
differed according to albuminuria status, we carried out a
stratified analysis in patients with sustained normoalbumin-
uria (ACR <2.5 mg/mmol in males and <3.5 mg/mmol in
females and with a duration of diabetes >15 years at end of
follow-up) and in those with any albuminuria (ACR
 2.5 mg/mmol in males and  3.5 mg/mmol in females,
either at baseline or at the end of follow-up).
To investigate if any of these SNPs were associated with a
rapid decline in renal function over the follow-up period, we
performed an analysis of time to stage 3B CKD
(eGFR<45 ml/min/1.73 m2). Individuals with stage 3B
CKD at baseline were excluded. By using this threshold,
4% of our patients were excluded from the analysis. If we
had chosen to study progression to stage 3A CKD
(eGFR<60 ml/min/1.73 m2), 20% of patients would have
been excluded from the analysis. Stage 3B CKD was defined
as three consecutive eGFR measurements of eGFR <45 ml/
min/1.73 m2 at least 1 month apart. Those who did not
progress to stage 3B CKD were censored at the end of the
follow-up period or at date of death. We used a Cox
proportional hazards model (the Proc PHREG tool in the SAS
statistical package), with date of birth as ‘time in’ and ‘last
date’ as the first date of eGFR <45 ml/min/1.73 m2 or the
end of follow-up period/date of death, and with genotype,
age, sex, BMI and baseline eGFR as covariates. The
interaction of individual SNPs with albuminuria was tested
using PLINK option ‘interaction’ with age, sex, BMI,
albuminuria and genotypes as covariates in the linear
regression model. We adopted a conservative threshold for
significance (0.05/number of loci tested) and a P value <
0.003 was considered to indicate statistical significance. A
weighted genetic risk score analysis was performed to test the
joint effect of the 16 loci on baseline eGFR and time to stage
3B CKD. We calculated weighted genetic risk score (number
of risk alleles*b) for each individual using all 16 SNPs, and
tested the association of this genetic risk score with baseline
eGFR and time to stage 3B CKD, adjusting for age, sex, BMI,
HbA1c, duration of diabetes, and systolic blood pressure. All
analyses were performed in PLINK version 1.07 [10] and SAS
What’s new?
• This is the first study comparing common genetic
variants associated with estimated GFR between the
general population and patients with Type 2 diabetes.
• This is the first report of the interaction of genetic
effects of estimated GFR-associated loci (UMOD
GCKR and SHROOM3) with albuminuria in patients
with Type 2 diabetes.
• The study stresses the need to adjust for albuminuria
while investigating the genetic determinants of renal
function.
Table 1 Demographic characteristics of the GoDARTs cohort
Characteristic, mean (SD) GoDARTs cohort in the present study GoDARTs cohort not included in the present study
Age at baseline, years 59.1 (11.0) 66.2 (11.6)
Sex,% female 46.4 42.3
Baseline BMI 30.6 (5.3) 31.5 (6.1)
Baseline eGFR, ml/min/1.73m2 73.9 (18.7) 70.9 (15.8)
Baseline systolic blood pressure, mmHg 142.8 (18.4) 141.7 (18.8)
Baseline HbA1C, mmol/mol 7.54 (1.3) (58 mmol/mol)* 7.3 (1.4) (56 mmol/mol)*
Baseline cholesterol, mmol/L 4.40 (0.97) 4.34 (0.91)
Duration of diabetes at baseline, years 8.71 (7.44) 7.75 (6.61)
*These are HbA1c values in IFCC units.
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9.2. Power calculations for quantitative traits were per-
formed using R 2.15.
Samples were genotyped at Affymetrix’s service laboratory
on the Genome-Wide Human SNP Array 6.0. Complete
genotype data have been described previously [11]. The study
complied with the Declaration of Helsinki guidelines. Since
October 1997, all individuals with diabetes in the GoDARTs
database have been invited to give consent for DNA
collection as part of the Wellcome Trust United Kingdom
Type 2 Diabetes case–control collection. As of June 2009,
8000 cases and 7000 control subjects of European ancestry
have participated in this GoDARTS study. Informed consent
was obtained from all the study participants.
Results
Table 1 shows the baseline characteristics of the GoDARTs
cohort included in the present study as well as the
GoDARTs cohort not genotyped at the conception of this
study. Genotype data were available for 3028 patients
(46.4% females) with Type 2 diabetes. Their mean (SD)
baseline BMI was 30.6 (5.3) kg/m2, mean (SD) age was 59.1
(11) years, mean (SD) HbA1c was 58 mmol/mol (7.54 (1.3).
The mean (SD) follow-up period for the entire study was
10.6 (9.1) years with a median of three eGFR readings/year/
person (interquartile range 2–4) and a mean (SD) baseline
eGFR of 73.9 (18.7) ml/min/1.73 m2.
Table 2 shows the association found for the 16 eGFR-
associated loci with baseline eGFR and albuminuria; the
study population was stratified by albuminuria status and the
association of these SNPs with time to stage 3B CKD. The
minor alleles ‘T’ of GCKR (b = 1.30, P-value = 3.23E-03),
and ‘T’ of UMOD (b = 2.0 P-value = 8.84E-04) were
associated with a higher eGFR at baseline and the minor
‘A’ of SHROOM3 (b = 1.28, P-value = 3.18E-03) was
associated with a lower eGFR at the predefined threshold
(P  0.003). None of the other SNPs was associated with
baseline eGFR. None of the 16 SNPs included in the study
were associated with albuminuria after correction for multi-
ple testing (data not shown). In patients with sustained
normoalbuminuria (n = 613), minor allele ‘T’ of UMOD
was associated with eGFR (b = 4.03, P-value = 1.10E-03),
while in patients with albuminuria (n = 2096) minor allele
‘T’ of GCKR (b = 1.12, P-value = 4.27E-02) and ‘A’ of
SHROOM3 (b = 1.43, P-value = 7.28E-03) were associ-
ated with eGFR. Of the 16 SNPs, UMOD (hazard
ratio = 0.83(0.70, 0.99), P-value = 0.03), PIP5K1B (hazard
ratio = 0.85(0.75, 0.96), P-value = 0.01) and SLC7A9 (haz-
ard ratio = 0.86(0.76, 0.98) P-value = 0.02) was associated
with time to stage 3B CKD (eGFR<45 mls/min/1.73 m2) at
the 0.05 threshold for significance. Although the PIP5K1B
locus was significant at P < 0.05, the direction of effect was
not consistent with a previous report by K€ottgen et al. [4]
and hence this cannot be regarded as a positive replication of
this SNP for its association with eGFR and time to CKD
stage 3B.
Since the variants tested in this study are associated with
age-related decline in eGFR in general population (and not
with any disease-specific decline) we used time-to-event
analysis with date of birth as the starting point; however, we
performed a sensitivity analysis in which we used the baseline
of GoDARTs study as the starting point. Although this
analysis decreases power because of a reduction in the
person-years follow-up, we see a similar effect size of
association with progression to stage 3B CKD. For example,
the hazard ratio of UMOD with time to stage 3B CKD with
the starting point as the GoDARTs study baseline (hazard
ratio = 0.87(0.74, 1.03) P-value = 0.1) is very similar to the
hazard ratio with date of birth as a starting point. The
weighted genetic risk score for the 16 SNPS explained the
1% variation in baseline eGFR and was significantly asso-
ciated with baseline eGFR after adjustments for age, sex,
BMI, HbA1c, duration of diabetes and systolic blood pressure
(P = 0.0026, b = 0.84(0.28). The weighted genetic risk
score was not associated with time to stage 3B CKD
(P = 0.52).
Discussion
In the present study, we replicated the association of
UMOD, GCKR and SHROOM3 with eGFR in patients
with Type 2 diabetes. The study confirms the findings of
previous studies showing the association of UMOD with
eGFR and diabetic nephropathy [12–15] and the association
of GCKR and SHROOM3 with eGFR [1,16,17]. A study
by Gudbjartsson et al. [12] demonstrated the interaction of
UMOD with age [15]; while another study could not
replicate this interaction. In the present study, we did not
observe an interaction of UMOD with age in patients with
Type 2 diabetes (P-value = 0.84).
None of the other variants were associated with eGFR
after correction for multiple testing; however, the direction
of effect was consistent with the previous studies for all the
statistically significant loci (GCKR, SHROOM3, UMOD)
and for the loci that did not pass the threshold of significance
(except TFDP2 and PIP5K1B). Our study had limited power
to estimate the effect of these variants on eGFR. Taken
together, all these variants explain the 1.4–14% heritability
of eGFR [5] (with each SNP contributing typically < 0.5%
heritability of eGFR). Our study had 97% power to detect an
association with a SNP explaining 0.5% variability in eGFR
and anything below 0.5% can remain undetected. It is also
possible that some of these SNPs are not the causal SNPs and
because of varying linkage disequilibrium, structure in our
population could not be detected. It is also possible that the
effects of some of these SNPs were attenuated by diabetes or
diabetic kidney disease and therefore were not associated
with eGFR in this study.
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We examined the association of the 16 loci with a decline
in renal function using a Cox proportional hazard model and
estimated the effect of these loci on time to stage 3B CKD
(eGFR<45ml/min/1.73 m2). Given the high mortality asso-
ciated with diabetic nephropathy, cross-sectional studies are
prone to survival bias, as patients with severe forms of
nephropathy are less likely to be included. Hence, it is
important to investigate the eGFR loci in a time-dependent
manner. Of the 16 SNPs, none were associated with time to
stage 3B CKD at the predefined threshold of 0.003, however,
UMOD and SLC7A9 were associated with time to stage 3B
CKD at the threshold of 0.05 (with the direction of effects
consistent with that reported previously). UMOD and
SLC7A9 have a stronger effect on baseline eGFR as
compared with other markers suggesting that SNPs with a
strong effect on baseline eGFR influence the decline in renal
function over time.
We performed a stratified analysis to examine the effect of
albuminuria on the known genetic associations with eGFR.
In Type 2 diabetic, nephropathy, albuminuria may be more
closely associated with decline in renal function and the
impact of genetic determinants of eGFR may differ depend-
ing on the presence or absence of nephropathy; therefore, we
examined the effects on eGFR stratified by albuminuria.
There is a clear difference in the effect sizes in those with
sustained normalbuminuria and those with albuminuria. For
example, the UMOD has twice the effect in patients with
sustained normalbuminuria as compared with those with
albuminuria (P-interaction = 0.002) while SHROOM3 (P-
interaction = 0.003) and GCKR (P-interaction = 0.08) had
larger effect sizes in those with albuminuria. It is known that
kidney diseases characterized by albuminuria, such as
diabetic nephropathy can have ultrafiltration and high eGFR
in the early stage of disease, while those characterized by
reduced renal function such as hypertensive kidney disease,
may be manifested with normoalbumiuria because of the
reduced renal efficiency [18,19]. Hence, studying the genetic
determinants of eGFR without adjusting for albuminuria
status or studying genetic determinants of albuminuria
without accounting for eGFR can reduce the power of these
studies to identify the true genetic effects. Cumulatively,
eGFR-associated loci explain only a small fraction of the
total heritable contribution eGFR and stratifying by albu-
minuria status in our existing genome-wide association study
datasets [3–5] can help us to uncover the missing heritability.
It is important to point out, however, that the interaction of
albuminuria with the genetic variants associated with eGFR
in patients with Type 2 diabetes seen in the present study is
the first report of this interaction in patients with Type 2
diabetes and needs to be confirmed in an independent
sample.
In summary, our results show that some of the genetic
determinants of eGFR in the general population are common
to patients with Type 2 diabetes; however, in patients with
Type 2 diabetes it is essential to adjust for albuminuria status
while investigating the genetic determinants of renal
function.
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